Healthcare / Drug Manufacturers - Specialty & GenericNasdaqGS
$4.85
-0.17 (-3.39%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 33% · confianza 22%
FCF escenarios
weak_data · normalized FCF $-18.1M · quality 34.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
9/100
F
Piotroski
2/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$182M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-2898.0%
↓Gross Margin
31.3%
↓Debt/Equity
97.92
↑TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2010–2025 · 15 años de histórico normalizado
Revenue CAGR
-4.0%
FCF CAGR
—
FCF margin
-10.6%
FCF / Net income
0.35x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $128.9M · net income $-38.7M · FCF $-13.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||||||||||
| Revenue | $128.9M | $128.9M | $128.3M | $103.3M | $111.3M | — | — | $557.6M | $524.2M | $532.3M | $541.1M | $539.3M | $476.8M | $441.7M | $317.6M | $276.7M | $238.2M |
| Net Income | $-38.7M | $-38.7M | $12.0M | $-99.6M | $-116.7M | — | — | $411000.00 | $24.8M | $10.6M | $-11.6M | $13.5M | $19.1M | $22.6M | $12.7M | $3.9M | $4.0M |
| EBITDA | $-8.5M | $-8.5M | $35.6M | $-33.2M | $12.8M | — | — | $20.7M | $26.0M | $25.3M | $-11.2M | $25.6M | $27.3M | $32.2M | $20.2M | $13.3M | $11.3M |
| EPS | -1.27 | -1.27 | 0.32 | -3.41 | -3.30 | — | — | 0.01 | 0.89 | 0.38 | -0.43 | 0.50 | 0.71 | 0.85 | 0.49 | 0.15 | 0.15 |
| Gross Margin | 31.3% | 31.3% | 32.6% | 27.1% | 35.1% | — | — | 14.5% | 14.9% | 14.9% | 12.3% | 12.1% | 13.1% | 14.2% | 16.4% | 16.9% | 14.2% |
| Operating Margin | -9.3% | -9.3% | -5.6% | -19.1% | -3.1% | — | — | 1.0% | 2.6% | 2.8% | -3.8% | 3.4% | 4.2% | 5.6% | 4.6% | 2.9% | 3.4% |
| Net Margin | -30.0% | -30.0% | 9.4% | -96.4% | -104.9% | — | — | 0.1% | 4.7% | 2.0% | -2.2% | 2.5% | 4.0% | 5.1% | 4.0% | 1.4% | 1.7% |
| Balance Sheet | |||||||||||||||||
| Debt/Equity | 97.92 | 97.92 | 11.37 | -26.63 | — | 0.80 | 0.39 | 0.32 | 0.15 | 0.19 | 0.22 | 0.16 | 0.14 | 0.19 | 0.27 | 0.11 | — |
| Cash Flow | |||||||||||||||||
| Free Cash Flow | $-13.6M | $-13.6M | $-18.1M | $-38.9M | $-52.5M | — | — | $-28.7M | $-13.8M | $6.8M | $-18.9M | — | — | $12.4M | $16.8M | $7.8M | $2.3M |
| Returns | |||||||||||||||||
| ROE | -2898.0% | -2898.0% | 106.2% | 2353.7% | — | — | — | 0.2% | 9.8% | 4.7% | -5.5% | 6.2% | 9.4% | 12.6% | 8.5% | 2.9% | — |
| Valuation | |||||||||||||||||
| P/E | — | — | 18.47 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| EV/EBITDA | — | — | 9.46 | — | 21.83 | — | — | — | — | — | — | — | — | — | — | — | — |
| P/B | 178.53 | 178.53 | 19.15 | — | — | — | — | — | — | — | — | — | — | — | — | — | — |
| Growth & Yield | |||||||||||||||||
| Revenue Growth | 0.5% | 0.5% | 24.2% | -7.2% | — | — | — | 6.4% | -1.5% | -1.6% | 0.3% | 13.1% | 7.9% | 39.1% | 14.8% | 16.2% | — |
| EPS Growth | -496.9% | -496.9% | 109.4% | -3.3% | — | — | — | -98.9% | 134.2% | 188.4% | -186.0% | -29.6% | -16.5% | 73.5% | 226.7% | 0.0% | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
-28.4%
Start / end P/E
n/dx → n/dx
EPS bridge
0.32 → -1.27
Residual
-28.4%
EPS/multiple decomposition requires positive EPS at both endpoints; residual absorbs price move not explained by dividends.
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.